Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Keyphrases

• Nivolumab 100%
• Clear Cell Renal Cell Carcinoma (ccRCC) 100%
• Anti-programmed Cell Death Protein 1 (anti-PD-1) 100%
• T Cells 33%
• Tumor 33%
• Tumor Samples 33%
• Mode of Action 33%
• Genomic Analysis 33%
• CD8+ T Cells 33%
• Clinical Response 33%
• Molecular Response 33%
• Molecular Features 33%
• T Cell Receptor 33%
• Similar Cluster 33%
• Response Predictors 33%
• Therapeutic Response 33%
• Highly Similar 33%
• Naïve Patients 33%
• T-cell Receptor Repertoire 33%
• Treatment-naïve 33%
• T Cell Clone 33%
• Pre-existing Immunity 33%
• Prospective Phase II Study 33%
• Multiregion 33%
• Metastatic Renal Cell Carcinoma (mRCC) 33%
• Human Endogenous Retrovirus 33%

Immunology and Microbiology

• T Cell Receptor 100%
• Nivolumab 100%
• T Cell 66%
• Antigen 66%
• Cytotoxic T-Cell 33%
• Endogenous Retrovirus 33%
• Cell Clone 33%
• Pretreatment 33%